See some of the latest developments, discoveries and commentaries from the WashU Medicine Department of Obstetrics and Gynecology.
For more news and updates:
Follow us on Twitter »
Listen to our Podcast »
Subscribe to our newsletter »
Media contact:
Jessica Church, Director of Media Relations – WashU Medicine Marketing & Communications
j.church@wustl.edu
2023 Gynecologic Oncology Fellowship Graduation
We said goodbye to Dr. Shaina Bruce and Dr. Elizabeth Stock. We hope to see you around soon.
Sara C. Wood, MD, named Chief of the Division of Female Pelvic Medicine & Reconstructive Surgery
“I am happy to announce that Sara C. Wood, MD, MHPE, FACOG, has accepted our offer to become the Chief of the Division of Female Pelvic Medicine & Reconstructive Surgery. Her clinical expertise and leadership will make her a valuable division and department member. We extend our warmest welcome and look forward to working with her. Dr. Wood […]
2023 Residency Graduation and Awards
We said goodbye to residents, welcome some back as fellows, and introduced a whole new team of interns! Read about the awardees below. Our Rothman Research Symposium is comprised of 2 half days where our residents, fellows, and basic science trainees present their OBGYN-related research projects which they have diligently worked on for a long […]
Welcome new 2023 Interns!
We are so excited to welcome our new interns! Welcome to Washington University School of Medicine, Obstetrics & Gynecology! We are happy you’re here. Emma Altieri – University of California – IrvineKatie Brow – Virginia Tech Carilion School of MedicineCat Burns – Indiana UniversityKatie Carbonell – Washington UniversitySarah Cohen – WashUKatie Howard – Medical College of Georgia at Augusta UniversityAli Houston-Ludlam – […]
Dr. Powell in “FDA to Decide on Dostarlimab Plus Chemo Approval in dMMR/MSI-H Advanced Endometrial Cancer in 4 Months”
The team presented the confirmatory additional endpoints of the Ruby trial which showed with the addition of dostarlimab immunotherapy added to chemotherapy for patients with advanced or recurrent endometrial cancer, there is a 71% improvement in progression-free survival or death for the biomarker-positive population and a 34% improvement in the overall population. Although we are […]